Ten-year trends in the use of catheter ablation for treatment of atrial fibrillation vs. the use of coronary intervention for the treatment of ischaemic heart disease in Australia

Europace

Volumn 15, Issue 12, 2013, Pages 1702-1709

  Kumar, Saurabh ^a   Walters, Tomos E ^a   Halloran, Karen ^a   Morton, Joseph B ^a   Hepworth, Graham ^a   Wong, Christopher X ^b   Kistler, Peter M ^c   Sanders, Prashanthan ^b   Kalman, Jonathan M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Atrial fibrillation; Catheter ablation; Coronary artery disease; Ischaemic heart disease; Percutaneous coronary intervention

Indexed keywords

AGING; ARTICLE; AUSTRALIA; CATHETER ABLATION; DATA BASE; GROWTH RATE; HEART ATRIUM FIBRILLATION; HUMAN; INTERMETHOD COMPARISON; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIC HEART DISEASE; MEDICARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREND STUDY; WELFARE;

ATRIAL FIBRILLATION; CATHETER ABLATION; CORONARY ARTERY DISEASE; ISCHAEMIC HEART DISEASE; PERCUTANEOUS CORONARY INTERVENTION;

ATRIAL FIBRILLATION; AUSTRALIA; CATHETER ABLATION; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; LINEAR MODELS; MYOCARDIAL ISCHEMIA; NEEDS ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84887367646     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut162     Document Type: Article

References (49)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125:e2-220.
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines. Europace 2006;8:651-745.
3. Benjamin EJ, LevyD, Vaziri SM,D'Agostino RB, Belanger AJ,Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-5.
5. Humphries KH, Jackevicius C, Gong Y, Svensen L, Cox J, Tu JV et al. Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can J Cardiol 2004;20: 869-76.
6. WattigneyWA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-6.
7. Wong CX, Brooks AG, Lau DH, Leong DP, Sun MT, Sullivan T et al. Factors associated with the epidemic of hospitalizations due to atrial fibrillation. Am J Cardiol 2012;110:1496-9.
8. Wong CX, Brooks AG, Leong DP, Roberts-Thomson KC, Sanders P. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med 2012;172:739-41.
9. Stewart S, Murphy NF,Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92.
10. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114: 119-25.
11. Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ et al. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. Eur Heart J 2001;22:693-701.
12. Simoons ML, Windecker S. Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization. Eur Heart J 2010;31: 530-41.
13. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
14. Pappone C, Oreto G, Lamberti F, Vicedomini G, Loricchio ML, Shpun S et al. Catheter ablation of paroxysmal atrial fibrillation using a 3D mapping system. Circulation 1999;100:1203-8.
15. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528-606.
16. Australian Institute of Health andWelfare. Procedure data cubes. http://www.aihw. gov.au/procedures-data-cubes/(22 July 2012, date last accessed).
17. Medicare Australia. Medicare Australia Statistics. http://www. medicareaustralia.gov. au/statistics/mbs-item.shtml (22 July 2012, date last accessed).
18. Australian Government Department of Health and Aging. Medicare Benefits Schedule Online. http://www.mbsonline.gov.au/(22 July 2012, date last accessed).
19. Australian Bureau of Statistics. 3101.0-Australian Demographic Statistics, December 2011. http://www.abs.gov.au/AUSSTATS/absnsf/DetailsPage/ 3101.0Dec2011 OpenDocument (22 July 2012, date last accessed).
20. Dorian P, JungW,NewmanD, Paquette M,Wood K, AyersGMet al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J AmColl Cardiol 2000;36:1303-9.
21. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448 e1-19.
22. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 2011;13:1375-85.
23. Rohrbacker NJ, Kleinman NL, White SA, March JL, Reynolds MR. The burden of atrial fibrillation and other cardiac arrhythmias in an employed population: associated costs, absences, and objective productivity loss. J Occup Environ Med 2010;52: 383-91.
24. Le Heuzey JY, Paziaud O, Piot O, Said MA, Copie X, Lavergne T et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004;147: 121-6.
25. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007;18:628-33.
26. Pappone C, Vicedomini G, Augello G, Manguso F, Saviano M, BaldiMet al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study. Circ Arrhythm Electrophysiol 2011;4: 808-14.
27. Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008; 118:2498-505.
28. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, SalibaWet al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634-40.
29. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303: 333-40.
30. Noheria A, Kumar A, Wylie JV Jr, Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008;168: 581-6.
31. Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009;2: 626-33.
32. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009;2:349-61.
33. Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010;122:2368-77.
34. Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up J Am Coll Cardiol 2011;57:160-6.
35. Sawhney N, Anousheh R, Chen WC, Narayan S, Feld GK. Five-year outcomes after segmental pulmonary vein isolation for paroxysmal atrial fibrillation. Am J Cardiol 2009; 104:366-72.
36. Medi C, Sparks PB, Morton JB, Kistler PM, Halloran K, Rosso R et al. Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up. J Cardiovasc Electrophysiol 2011;22:137-41.
37. Tzou WS, Marchlinski FE, Zado ES, Lin D, Dixit S, Callans DJ et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:237-42.
38. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS et al. Long-term outcomes of catheter ablation of atrial fibrillation: a Systematic review and meta-analysis. J Am Heart Assoc 2013;2:e004549.
39. Reynolds MR,Walczak J, White SA, Cohen DJ, Wilber DJ. Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. Circ Cardiovasc Qual Outcomes 2010; 3:615-23.
40. WeerasooriyaR, Jais P, Le Heuzey JY, Scaveé C,Choi KJ, Macle L et al. Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2003;26: 292-4.
41. Khaykin Y, Morillo CA, SkanesAC, McCracken A, Humphries K, Kerr CR. Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:907-13.
42. Khaykin Y, Wang X, Natale A, Wazni OM, Skanes AC, Humphries KH et al. Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: an economic evaluation of the RAAFT pilot study. J Cardiovasc Electrophysiol 2009;20:7-12.
43. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ et al. Costeffectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 2009;2: 362-9.
44. Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess 2008;12:iii-iv, xi-xiii, 1-198.
45. Lee G, Sparks PB, Morton JB, Kistler PM, Vohra JK, Medi C et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol 2011;22:163-8.
46. Sivagangabalan G, Ong AT, Narayan A, Sadick N, Hansen PS, Nelson GC et al. Effect of prehospital triage on revascularization times, left ventricular function, and survival in patients with ST-elevation myocardial infarction. Am J Cardiol 2009;103:907-12.
47. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, KostukWJet al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503-16.
48. Ahmed B, Dauerman HL, Piper WD, Robb JF, Verlee MP, Ryan TJ Jr et al. Recent changes in practice of elective percutaneous coronary intervention for stable angina. Circ Cardiovasc Qual Outcomes 2011;4:300-5.
49. Wissner E, Stevenson WG, Kuck KH. Catheter ablation of ventricular tachycardia in ischaemic and non-ischaemic cardiomyopathy: where are we today A clinical review. Eur Heart J 2012;33:1440-50.